Fannie Mae, Freddie Mac shares tumble after conservatorship comments
PLEASANTON, Calif. - Veeva Systems (NYSE: VEEV), a cloud software provider for the life sciences industry valued at $46.5 billion, has announced that pharmaceutical company Astellas will implement Veeva Vault CRM as its standard for commercial operations worldwide, including a specialized version for China. The company, which has demonstrated robust growth with a 14.78% revenue increase over the last twelve months, continues to expand its market presence.
Nick Eshkenazi, Astellas’ chief digital and transformation officer, emphasized the importance of commercial agility and execution in delivering transformative therapies to patients globally. He expressed confidence that the partnership with Veeva would enhance the company’s agility through advanced technology solutions and data management.
Veeva’s Vault CRM is designed to meet the distinct business needs and regulatory requirements across different countries. The software is part of the Vault CRM Suite, which aims to facilitate collaboration among sales, marketing, and medical teams for more effective commercial execution. According to InvestingPro data, Veeva maintains excellent financial health with a current ratio of 4.6 and holds more cash than debt on its balance sheet, indicating strong operational stability.
Veeva Systems, recognized as a global leader in cloud software for the life sciences sector, supports over 1,000 customers, including large biopharmaceutical firms and emerging biotechs. As a Public Benefit Corporation, Veeva pledges to balance the interests of various stakeholders, such as customers, employees, shareholders, and the industries it serves.
The company’s forward-looking statements in the press release indicate anticipated benefits from the use of its products and services, though they caution that actual results may vary. Potential risks that could affect outcomes are detailed in Veeva’s recent SEC filings, including its Form 10-Q for the period ending April 30, 2025. Recent market performance has been notably strong, with the stock showing a 21.43% return over the past week. For deeper insights into Veeva’s valuation and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 top US stocks.
This partnership announcement is based on a press release statement and does not imply any endorsement of the claims made. It is intended to provide factual information regarding the collaboration between Veeva Systems and Astellas in adopting Veeva Vault CRM for commercial operations.
In other recent news, Veeva Systems reported strong financial results for the first fiscal quarter of 2026, leading several analysts to adjust their price targets for the company. Mizuho increased its price target to $295, citing significant contributions from Veeva’s Crossix Solution and an increase in earnings per share estimates for fiscal years 2026 and 2027. Jefferies also raised its target to $335, highlighting robust margins and growth in Veeva’s commercial operations despite challenges in the pharmaceutical supply chain sector. TD Cowen adjusted its price target to $284, noting exceptional results from Veeva’s Crossix business and revised revenue and billing guidance. Citi increased its target to $329, emphasizing Veeva’s outperformance in revenue and billings, as well as the strong demand for its Crossix solutions. RBC Capital Markets raised its target to $330, crediting Veeva’s strong subscription growth and management’s ability to navigate macroeconomic uncertainties. Each of these analyst firms maintained positive ratings on Veeva, reflecting confidence in the company’s ongoing performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.